Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastric Cancer Prevention Strategies Based on Eradication of High-Risk Helicobacter Pylori Subtypes
NCT06943794Not yet recruiting
- Sponsor
- Fudan University
- Start
- Mar 2026
- Primary completion
- May 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of omeprazole, bismuth subcitrate, metronidazole and tetracycline in gastric cancer (GC) (2 arms), sponsored by Fudan University. Primary endpoint: Five-year gastric cancer incidence at 5 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
omeprazolebismuth subcitratemetronidazoletetracycline
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06943794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943794.